



Gill Harvey, Kathryn Oliver, John Humphreys, Katy Rothwell, and Janet Hegarty 
Improving the identification and management of chronic kidney disease in primary 
care: lessons from a staged improvement collaborative 
International Journal for Quality in Health Care, 2014; 27(1):10-16 
 
 
© The Author 2014. Published by Oxford University Press in association with the 
International Society for Quality in Health Care. This is an Open Access article distributed 
under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, 

































Date viewed – 12 March 2015 
Article
Improving the identiﬁcation and management of
chronic kidney disease in primary care: lessons
from a staged improvement collaborative
GILL HARVEY1,2, KATHRYN OLIVER3,4, JOHN HUMPHREYS5,
KATY ROTHWELL5, and JANET HEGARTY6
1Manchester Business School, University of Manchester, Booth Street West, Manchester M15 6PB, UK, 2School of
Nursing, University of Adelaide, Eleanor Harrald Building, Frome Road, Adelaide SA5005, Australia, 3School of Social
Sciences, University of Manchester, Arthur Lewis Building, Oxford Road, Manchester M13 9PL, UK, 4Department for
Science, Technology, Engineering and Public Policy (UCL STEaPP), University College London, 36-38 Fitzroy Square
(2nd Floor), LondonW1T 6EY, UK, 5NIHR CLAHRC for Greater Manchester, 3rd Floor, Mayo Building, Salford Royal NHS
Foundation Trust, Stott Lane, Salford M6 8HD, UK, and 6Renal Department, Salford Royal NHS Foundation Trust, Stott
Lane, Salford M6 8HD, UK
Address reprint requests to: Gill Harvey, Professor of Health Management, Manchester Business School, Harold Hankins
Building, Booth Street West, Manchester M15 6PB, UK. Tel: +44-161-3063472; E-mail: gill.harvey@mbs.ac.uk
Accepted 31 October 2014
Abstract
Quality problem: Undiagnosed chronic kidney disease (CKD) contributes to a high cost and care bur-
den in secondary care. Uptake of evidence-based guidelines in primary care is inconsistent, resulting
in variation in the detection and management of CKD.
Initial assessment: Routinely collected general practice data in one UK region suggested a CKD
prevalence of 4.1%, compared with an estimated national prevalence of 8.5%. Of patients on CKD
registers, ∼30% were estimated to have suboptimal management according to Public Health Obser-
vatory analyses.
Choice of solution: An evidence-based framework for implementation was developed. This in-
formed the design of an improvement collaborative to work with a sample of 30 general practices.
Implementation: A two-phase collaborative was implemented between September 2009 andMarch
2012. Key elements of the intervention included learning events, improvement targets, Plan-Do-
Study-Act cycles, benchmarking of audit data, facilitator support and staff time reimbursement.
Evaluation: Outcomes were evaluated against two indicators: number of patients with CKD on prac-
tice registers; percentage of patients achieving evidence-based blood pressure (BP) targets, as amark-
er for CKD care. In Phase 1, recorded prevalence of CKD in collaborative practices increased ∼2-fold
more than that in comparator local practices; in Phase 2, this increased to 4-fold, indicating improved
case identiﬁcation. Management of BP according to guideline recommendations also improved.
Lessons learned: An improvement collaborative with tailored facilitation support appears to pro-
mote the uptake of evidence-based guidance on the identiﬁcation and management of CKD in pri-
mary care. A controlled evaluation study is needed to rigorously evaluate the impact of this
promising improvement intervention.
Key words: improvement collaborative, chronic kidney disease, primary care, implementation, evidence-based guidance
International Journal for Quality in Health Care, 2015, 27(1), 10–16
doi: 10.1093/intqhc/mzu097
Advance Access Publication Date: 18 December 2014
Article
© The Author 2014. Published by Oxford University Press in association with the International Society for Quality in Health Care.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
10







Chronic kidney disease (CKD) is a progressive loss of kidney function
over a period of at least 3 months. Since 2002, a system of classifying
CKD according to ﬁve stages has been applied [1] (see Table 1). Many
patients with CKD Stages 3–5 are not identiﬁed until the disease is ad-
vanced. 1.3 and 19.9% of patients at Stages 3 and 4, respectively, will
progress to end-stage kidney disease (ESKD) within 5 years [2]. This is
costly for health care systems and patients alike, with ESKD requiring
a burdensome and costly treatment programme in secondary care.
Asymptomatic patients at all (including the early) stages of disease
also have an increased risk of hospitalization through both cardio-
vascular events and acute kidney injury [3]. The prevalence of CKD
in the adult population is debated; estimates in the UK suggest a popu-
lation average between 6.76 and 8.5% [4, 5], a ﬁgure that varies ac-
cording to age, sex, ethnicity and co-morbidity. Prevalence increases
exponentially with age; thus with current demographic trends, CKD
is likely to become an increasingly important public health issue.
National and international evidence-based clinical guidelines have
been developed to promote the identiﬁcation and improved manage-
ment of CKD Stages 3–5 [1, 6]. In the UK, case ﬁnding for CKD has
also been ﬁnancially incentivized since 2006 through a primary care
pay-for-performance scheme known as the Quality and Outcomes
Framework (QOF) [7]. These initiatives recognize the potential for im-
proving the diagnosis and management of CKD patients in primary
care, in terms of enhancing patient outcomes and quality of life and
realizing signiﬁcant cost savings for health care systems in the longer
term. Despite these initiatives, identiﬁcation of early-stage CKD in pri-
mary care remains inconsistent [8].
Initial assessment
The project was undertaken in Greater Manchester, a region in the
north of England with a poor overall life expectancy [9]. In 2008,
the National Institute for Health Research (NIHR) Collaboration
for Leadership in Applied Health Research and Care (CLAHRC)
Greater Manchester was established with the aim of reducing inequal-
ities in vascular disease through conducting and implementing applied
health research. CKDwas identiﬁed as one of the areas to be addressed
within this programme of work. QOF data for 2008/09 recorded the
prevalence of CKD in Greater Manchester as 4.1% [10], considerably
lower than national population estimates, based on available research
evidence, of ∼8.5% [4]. Of the patients identiﬁed on general practice
registers, QOF data showed that ∼30% had suboptimal management,
deﬁned as uncontrolled or unknown blood pressure (BP) [10].
These data demonstrated the potential for improvement as al-
though patients with CKD are often asymptomatic, they can be iden-
tiﬁed reasonably easily through routine clinical tests, such as blood
biochemistry and urinalysis. Moreover, they often have co-morbidities
and are on other primary care disease registers. The challenge was to
ﬁnd a way to effectively translate the available evidence on identifying
and managing CKD into primary care practice (see Box 1).
Choice of solution
An evidence-based implementation framework was developed, draw-
ing upon available research about effective strategies for implementing
evidence-based recommendations into practice. This framework com-
prised a number of elements, which have previously been described
[11]. Brieﬂy, they comprised a conceptual framework – the Promoting
Action on Research Implementation in Health Services framework
[12] – which proposes that successful implementation is dependent
on the nature of the evidence to be implemented, the context in
which implementation takes place and the way in which the process
is facilitated. Within these conceptual co-ordinates of evidence, con-
text and facilitation, a modiﬁed version of theModel for Improvement
was identiﬁed as an operational framework to guide implementation,
with its emphasis on establishing and measuring targets for improve-
ment and using Plan-Do-Study-Act (PDSA) cycles to work towards
established goals [13]. In order to support the implementation process,
two additional elements were incorporated: multi-disciplinary teams
made up of improvement facilitators, project managers, information
specialists, clinicians and academics to plan, lead and support the
improvement programme; an embedded approach to evaluation and
learning to ensure ongoing reﬂection on and reﬁnement of the im-
provement programme.





1. Kidney damage with normal
or raised GRF
>90
2. Kidney damage with mildly
reduced GFR
60–89
3. Moderately reduced GRF 30–59
4. Severe reduction in GFR 15–29
5. Kidney failure <15
Box 1 Guideline recommendations for the identiﬁcation
and management of adult patients with CKD in primary
care
In primary care in the UK, NICE CKD guidelines (2008) rec-
ommend that:
–People should be offered testing for CKD whether
they have risk factors such as diabetes, hypertension,
cardiovascular disease, family history of Stage 5 CKD
or hereditary kidney disease or whether there is op-
portunistic detection of haematuria or proteinuria;
–Testing should include obtaining a minimum of three
estimated glomerular ﬁltration rates (eGFR) over a
period of <90 days;
–IdentiﬁedCKDpatients coded at Stage 3A/B should be
monitored every 6 months in general practice by
eGFR testing. This is adjusted to every 3 months or
every 6 weeks, if the patient is coded at Stages 4 or
5, respectively;
–For CKD patients without proteinuria, BP should be
managed within the range <140/90; for patients with
proteinuria, the range should be <130/80;
–Stable Stage 4 cases should ideally bemanagedwith-
in primary care, whereasmore complicated cases and
those at Stage 5 should bemonitored by renal specia-
lists;
–Proteinuria status and BP should be monitored for all
CKD patients at least annually.
Source: NICE (2008) [6].
Chronic kidney disease improvement collaborative • Quality improvement 11






Following stakeholder consultation within the primary care set-
ting, an improvement collaborative (see Box 2) was selected as an ap-
propriate way to structure the planned project. This was seen to be
relevant for a number of reasons: ﬁrst, the need to work with multiple
general practices at the same time; second, the fact that collaborative
methodology builds on the Model for Improvement [15]; third, a rec-
ognition of the potential beneﬁts to be achieved through bringing
members of different general practice teams together to learn and
share experiences.
Implementation
The ﬁrst step involved establishing an expert faculty to review the evi-
dence on CKD and agree the scope and aims of the collaborative. The
faculty included clinical staff from primary and secondary care, pa-
tient representatives and individuals with expertise in improvement.
Two overarching objectives were established: to halve the gap between
recorded and estimated prevalence and to ensure that 75% patients
with recorded CKD had their BP managed according to the targets re-
commended in national guidelines [6] (<140/90 for patients without
proteinuria; <130/80 for patients with proteinuria). BP management
was identiﬁed as the measure reﬂecting the overall quality of CKD
care as it links to progression of CKD and cardiovascular outcomes.
Phase 1 collaborative
Nineteen practices from four administrative areas within Greater Man-
chester took part in Phase 1. The project budget was sufﬁcient to sup-
port involvement of 4–5 practices per area (representing 7–10% of the
practice population). Practices were recruited by a mix of self-selection
following advertisement of the initiative and nomination by local NHS
managers. Recruited practices represented different sizes (as measured
by patient 18+ list size, range 1671–9974) and adult CKD prevalence
at baseline (range 1.5–5.9%). Once enrolled, practices were invited to
the ﬁrst of three joint learning events. Each practice was encouraged to
send three staff members who would form the practice improvement
team. To reﬂect the multi-disciplinary nature of the project, it was sug-
gested that the improvement team should include General Practitioner,
nursing and administrative representation. The ﬁrst learning event in-
troduced the improvement collaborative methodology, CKD guidelines
and improvement targets for the collaborative. Subsequent learning
events addressed issues such as building effective improvement teams,
creating a receptive context for change and sustaining improvements
in practice. Between the learning events, improvement teams were ex-
pected to test and apply planned changes using PDSA cycles. Two facil-
itators made regular practice visits to support the improvement process
and provide help with activities such as data searches, managing prac-
tice registers, developing process maps and advising on how to over-
come particular barriers or problems. This latter activity was
informed by an initial assessment of the practice context to identify fac-
tors that could facilitate or impede improvement, for example, the way
in which the practice was usually run, issues of leadership and culture,
the level of teamwork and communication.
All practices were required to submit monthly data relating to the
numbers of patients on the CKD register, numbers tested for protein-
uria and the number of patients with BPmanaged to target. These data
were analysed by the project team and reported back to practices on a
monthly basis in the form of run charts, which presented progress
against the key indicators over time both for their own practice and
the collaborative as a whole. This allowed individual practices to
benchmark progress against their peers; it also enabled the improve-
ment facilitators to identify areas where more targeted input and sup-
port was required.
At project inception stakeholder input had indicated that uptake of
the improvement programme would only be possible with staff time
reimbursement. As part of the implementation strategy, therefore,
practices received ﬁnancial resources to secure protected time for im-
provement teams; different practices spent this in different ways in-
cluding locum doctor cover to release physicians for improvement
work and buying additional hours from practice staff. In addition in
Phase 1, a small additional per patient paymentwasmade for complet-
ing key stages of the improvement process (baseline data collection and
attendance at the three learning sessions).
Moving from Phase 1 to Phase 2
At the end of Phase 1, a closing meeting was held to share the experi-
ences and successes of the participating practices. The facilitation team
also reﬂected on the learning gained during the collaborative, in-
formed by the formative evaluation that had been ongoing throughout
the implementation process (and which is detailed more fully in the
following section). This led to the development of a CKD improve-
ment guide, which summarized the key activities involved in im-
plementation: creating a foundation for improvement, identifying
patients with CKD, achieving optimal management of patients with
CKD and ensuring improvements are sustained [14]. This guide, com-
plete with accompanying resources and links to other useful available
information, was made available as an online resource [16]. It also
led to discussions with a CLAHRC initiative in another region of
the country that had been involved in developing a data extraction
and audit tool to analyse practice registers in relation to patients
with CKD. The two CLAHRCs agreed to collaborate to develop a
programme known as IMPAKT™ (IMproving Patient care and
Awareness of Kidney disease progression Together).
Phase 2 collaborative
The IMPAKT™ tool [17] formed a central part of the evidence and im-
plementation resource for Phase 2 of the improvement collaborative.
Other changes from Phase 1 included the appointment of a practice
nurse from one of the practices that had been involved in the Phase
1 collaborative to work as a facilitator within the CLAHRC team.
Box 2 Description of the improvement collaborative ap-
proach [14]
• Based on the Institute for Healthcare Improvement
breakthrough series approach;
• Brings together subject matter experts and practi-
tioners to test and implement changes in care within
a structured, experiential learning framework;
• Teams commit to working on a common topic over a
period of ∼12 months, with shared goals and an
agreed measurement strategy;
• Teams alternate between shared learning events (to
exchange ideas and encourage learning across
teams) and action periods (using the Model for
Improvement to test small ideas in the workplace);
• An agreed change package is used, with regular mon-
itoring and feedback of progress against targets.
12 Harvey et al.






This brought the beneﬁts of someone with insider knowledge of
the practice environment and the improvement process, as well as
local political knowledge and longstanding local professional relation-
ships. Due to ﬁnancial constraints within the health care sector and the
wider CLAHRC programme, the payments available to participating
practices were reduced and the collaborative learning events were
reduced from three events to two and from a full to half day. Addition-
al opportunities for meeting and sharing experiences were, however,
provided through ﬁve WebEx seminars scheduled at the outset of
the project.
Selection was different in Phase 2 as 10 of the 11 practices were
from the same geographical and administrative area of Greater Man-
chester (which had 5 practices involved in the ﬁrst collaborative and
fromwhere the practice nurse facilitator was seconded). This was a de-
liberate strategy building on the local proﬁle of the initiative and util-
izing the seconded facilitator’s pre-existing relationships to assist with
engagement. The facilitators liaised with in-house information tech-
nology experts to install IMPAKT™ and then worked with practices
to interpret and use data from the tool, as part of the process of inter-
rogating and verifying practice registers to identify patients with CKD.Figure 1 Change in recorded prevalence by month.
Figure 2Comparison of change in prevalence rates over time: intervention vs. non-intervention sites. (a) Phase 1 collaborative (QOF reporting iswithin annual period
from April to March. The Phase 1 collaborative ran from September 2009 to 2010; therefore, the comparison with non-collaborative practices is made over the
two relevant QOF cycles of reporting). (b) Phase 2 collaborative.
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As in Phase 1, once patients with CKD were identiﬁed, the focus
turned to achieving optimal patient management.
Evaluation
Each practice had its own prevalence target to achieve, depending on its
starting position and an estimated prevalence value, which was mod-
elled on a practice by practice basis using research evidence produced
by Public Health England [18]. Overall, the number of patients on
CKD registers increased by 1863. In both Phases 1 and 2, there was a
recorded 1.2% increase in prevalence. In Phase 1, 1324 additional pa-
tients were added to registers; this represented 92% achievement of the
original aim set (n = 1441) to halve the gap between recorded and esti-
mated prevalence of CKD. Ten of the 19 practices achieved the target. In
Phase 2, 539 additional patients were identiﬁed, equivalent to 154%
achievement of the target. Overall, the target was achieved by Month
3, and 7 of the 11 participating practices reached the target by the
close of the project (see Fig. 1). Comparing Phase 1 with 2, the baseline
prevalence in Phase 1 was lower than that in Phase 2, which in turn
made the average prevalence increase to be achieved greater (2.5% com-
pared with 1.4%). In order to assess the improvements made in the
collaborative sites, we compared their pre- and post-intervention preva-
lence rates with QOF data over the same time periods for non-
collaborative sites within the same area and with national averages
(see Figs 2a and b). These data indicate improved identiﬁcation of
patients with CKD in collaborative practices compared with both
local and national comparators. Interestingly, in the ﬁrst time period,
there were general increases in prevalence, most likely driven by the
pay-for-performance system and stepwise improvements in awareness
of CKD. The collaborative practices still demonstrated an approximate
2-fold increase in CKD prevalence compared with local comparators.
During 2011–12, there was little or no change in prevalence achieved
locally or nationally (Fig. 2b), but the improvement practices showed
a 4-fold increase in their CKD prevalence.
In relation to the second aim, management of BP improved in both
phases; from34 to 74%of patientsmanaged toNICE targets in Phase 1
and an increase from 60 to 83% in Phase 2 (see Fig. 3). Nine of the 19
practices achieved the 75% target in Phase 1 and all 11 practices
reached it in Phase 2. In order to assess the progress made by collabora-
tive practices, we analysed the QOF pay-for-performance data from the
geographical region that had the greatest level of involvement in Phases
1 and 2 of the project. The actual timeframes for QOF reporting do not
exactly match the time periods during which the collaboratives took
place; however, looking over the total timeframe of the project, there
is evidence to suggest that collaborative practices reported better levels
of BP management in their CKD population (see Table 2).
Despite the overall level of achievement being close to or above the
targets set, variation between practices occurred as apparent from the
number of practices that failed to achieve speciﬁc targets, particularly
in Phase 1. The process evaluation helped to illuminate the factors
that contributed to the observed variation. In Phase 1, we analysed
the process of implementation through a number of different
Figure 3 Percentage of CKD patients with blood pressure managed to NICE targets by month.
Table 2 Comparison of diagnosed CKD patients within one
geographical region treated to national pay-for-performance (QOF)
blood pressure targets by involvement in the improvement
collaborative
Time period % achievement of
target BP in CKD
collaborative practices
% achievement of





The difference between the QOF and NICE blood pressure targets was that
testing for proteinuria was a pre-requisite of meeting the NICE target. This
accounts for the lower baseline ﬁgures reported in the collaborative sites
when comparing against NICE targets.
14 Harvey et al.






approaches: monthly review of individual practices at project team
meetings, informal interviews and discussions with practice staff dur-
ing practice-facilitator meetings and asking practices to review and
rate their own progress at the learning events. In Phase 2, the ongoing
formative evaluation was supplemented by a more in-depth qualita-
tive study in the ﬁnal stages of the collaborative (January to April
2012) to gain greater insight into the mechanisms and processes
that contributed to project outcomes [19].
Common enabling factors included the learning events, the sup-
port of the facilitators, having clearly deﬁned targets, regular feedback
of data and ﬁnancial support to participate in the collaborative. A spe-
ciﬁc barrier that many practices faced in Phase 1 was difﬁculty extract-
ing the required data on CKD from practice registers, due to a lack of
knowledge and skills or problems with the system itself. This was
something that the introduction of IMPAKT™ helped to overcome.
Other factors could act as an enabler (if present) or a barrier (if absent)
and appear to account for the variation that was observed in achieve-
ment of the collaborative goals. These included the priority attached to
CKD as a topic for improvement; the support of senior leadership; the
receptivity of the practice context to new ideas and change; the extent
of wider staff engagement in the improvement project, beyond the
designated improvement team (see Box 3 for illustrative quotes).
Lessons learned
Through working together on the improvement of CKD over a period
of 30 months, a number of important lessons emerged. First, the ap-
plication of an improvement collaborative methodology, informed by
an evidence-based implementation framework, appears to have en-
abled increased identiﬁcation and improved management of patients
with CKD in primary care, over and above that which could be attrib-
uted to the national pay-for-performance system (QOF). Key features
of the improvement collaborative (shared learning and networking,
clear improvement targets, regular audit and feedback) plus a dedi-
cated practice facilitator providing tailored support appear to act as
important enablers of improvement. This concurs with ﬁndings
from other studies of practice facilitation; a recent systematic review
suggests that practices supported by a facilitator are almost three
times more likely to implement clinical guidelines [20].
Second, our experience highlights the beneﬁts of adopting a longi-
tudinal approach to improvement work in terms of achieving greater
efﬁciencies and accelerating the rate of improvement. Through the
course of running two sequential collaboratives, we have accumulated
learning about the management of CKD, resulting in the development
and continuous reﬁnement of practical resources to be used by
improvement teams and a greater understanding of the contextual
variables that need to be addressed to facilitate more tailored – and ul-
timately more successful – implementation.
Third, we have begun to develop an external–internal model of fa-
cilitation within local primary care practice. We believe this is an im-
portant area for future development to build capacity for improvement
within primary care and enhance sustainability over the longer term.
Practice-based facilitation is an area of growing interest and activity
[21, 22] and one that clearly involves a substantive investment in
terms of people, time and resources. There are many questions still
to be answered to better understand the appropriate balance between
investment costs and beneﬁts realization, for example: who should
take on the facilitator role? How best to identify, prepare, develop
and support facilitators? What dose and frequency of facilitator inter-
vention works best? These are important questions to answer in future
Box 3 Qualitative experiences of participants in the Phase
2 collaborative
Enablers of improvement:
‘We had the long ﬁrst session, which was great, but for
the other people (the facilitator) did a half an hour with
them to get them up to speed with what was going
on. . . . We could have probably done this ourselves, but
having someone come in from outside made it clearer to
them that it wasn’t just something that we decided to do
on a whim, but that it was actually part of a bigger project
we were involved in’. (Clinical coordinator)
‘(The support has been) excellent. I’ve really enjoyed it.
I have found the support excellent from both of them. I am
the only practice nurse in the practice, so it’s been nice
that (the clinical facilitator) has come in from a practice
nurse point of view and she’s been a fantastic support.
Really, in a way, it’s a bit like clinical supervision as well
because we’ve discussed other things’. (Practice Nurse)
‘I feel that with the support I’ve had, I am more conﬁ-
dent talking to patients. When we sent the initial letters
out some patients were coming in and saying I haven’t
got kidney disease. It hadn’t been discussed with them
previously. So that needed a little bit of work around
and explaining about what chronic means because a lot
of people thought it meant severe, whereas to us it’s
chronic, long term’. (Practice Nurse)
‘There’s a kind of structure to it and I think it needs that
really. You need to have certainty to get the building
blocks in place. But, I think that once you’ve got those
building blocks in place and because of the knowledge
that you get over time going through the year, when you
come to sort of taking things on yourself, it’s all in place
for you to continue’. (GP)
Barriers to improvement:
‘It was the initial education and time needed to get the
register validated and then put a protocol together (that took
the time). . . . But that initial work is done now, it wouldn’t
need to be repeated again and it’s just a routine thing that
everyonedoesnow,so it’spaidoff in theend’. (PracticeNurse)
‘I tried to coordinate (the project) really, blocking out
time so that people had time to devote to it. There was a
bit of a battle over the time at ﬁrst and management just
thought that it could just happen in clinic time and we
have had to ﬁght for that’. (Practice Administrator)
‘If I was ever involved in a project like this again, it’s one of
the thingsthat Iwouldreallystickmyneckouton isthat therest
of thepracticewasn’t involvedearlyenough. Ifwe’dhadmore
involvementfromtheothersearlier itwouldhavesavedusalot
ofworkbecausealotoftheresultsandthingsthatwerecoming
in that we’d instigatedweren’t necessarily coming through to
us so again, theywere being ﬁled as normal or weren’t being
coded. It was then just doublework’. (Practice Nurse)
‘It’snouse(thepracticenurse)andIgoingthroughall these
codes if the rest of the practice (team) aren’t going to do it. For
me thatwas themost important thing. It can’t just be twopeo-
ple doing it. It has to be thewhole practice staff. . . . Every sin-
gle person that sees patients needs to have some grasp of
what’s going on, even to the point of the admin staff because
they are sending out letters for annual reviews’. (GP)
Chronic kidney disease improvement collaborative • Quality improvement 15






work to maximize the cost-effectiveness of large-scale improvement
interventions in primary care.
Finally, it is important to acknowledge the limitations of the
approach we have taken as our work to date has adopted a pre–
post-test design, without matched controls. As such, we cannot
claim causality for the improvements achieved. However, we have de-
veloped and reﬁned a complex intervention to support the identiﬁca-
tion and management of adult patients with CKD in primary care.
Future research can target rigorous evaluation of this promising im-
provement intervention, which encompasses both technological
(audit software) and social (behaviour change) components.
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